Absci and PrecisionLife announced a collaboration to develop a joint portfolio of potential therapeutics addressing unmet medical needs. The collaboration combines Absci’s speed and strength in antibody design and optimization with PrecisionLife’s deep understanding of complex disease biology and expertise in identifying the mechanisms, drug targets and treatments that are relevant to specific patients to create a pipeline of novel biotherapeutics. Under the partnership, Absci and PrecisionLife will work together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications, then jointly evaluate options to most effectively advance programs against such targets. Absci and PrecisionLife will actively collaborate to select chronic disease drug targets linked to patients with unmet clinical needs and maximize the innovation potential of their respective approaches. The Partners will share in the potential value of programs developed against any specific targets. With this new partnership, Absci has now signed ten new Active Programs this year, achieving the Company’s outlook for 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABSI:
- Absci management to meet virtually with William Blair
- Absci initiated with bullish view at KeyBanc, here’s why
- Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
- Absci enters collab with AstraZeneca to advance AI-driven oncology candidate
- AstraZeneca, Absci tie up on cancer drug, FT reports